| Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer B Wingelhofer, HA Neubauer, P Valent, X Han, SN Constantinescu, ... Leukemia 32 (8), 1713-1726, 2018 | 238 | 2018 |
| Pharmacologic inhibition of STAT5 in acute myeloid leukemia B Wingelhofer, B Maurer, EC Heyes, AA Cumaraswamy, A Berger-Becvar, ... Leukemia 32 (5), 1135-1146, 2018 | 158 | 2018 |
| STAT3 promotes melanoma metastasis by CEBP-induced repression of the MITF pathway A Swoboda, R Soukup, O Eckel, K Kinslechner, B Wingelhofer, ... Oncogene 40 (6), 1091-1105, 2021 | 65 | 2021 |
| O-GlcNAcylation of STAT5 controls tyrosine phosphorylation and oncogenic transcription in STAT5-dependent malignancies P Freund, MA Kerenyi, M Hager, T Wagner, B Wingelhofer, HTT Pham, ... Leukemia 31 (10), 2132-2142, 2017 | 61 | 2017 |
| High activation of STAT5A drives peripheral T-cell lymphoma and leukemia B Maurer, H Nivarthi, B Wingelhofer, HTT Pham, M Schlederer, T Suske, ... Haematologica 105 (2), 435, 2019 | 53 | 2019 |
| The ERBB-STAT3 axis drives Tasmanian devil facial tumor disease L Kosack, B Wingelhofer, A Popa, A Orlova, B Agerer, B Vilagos, P Majek, ... Cancer Cell 35 (1), 125-139. e9, 2019 | 49 | 2019 |
| Fibroblast growth factor receptor 4: A putative key driver for the aggressive phenotype of hepatocellular carcinoma C Gauglhofer, J Paur, WC Schrottmaier, B Wingelhofer, D Huber, ... Carcinogenesis 35 (10), 2331-2338, 2014 | 49 | 2014 |
| Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia G Deb, B Wingelhofer, FMR Amaral, A Maiques-Diaz, JA Chadwick, ... Leukemia 34 (5), 1266-1277, 2020 | 40 | 2020 |
| Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies L Nicosia, GJ Spencer, N Brooks, FMR Amaral, NJ Basma, JA Chadwick, ... Cancer Cell 41 (12), 2136-2153. e13, 2023 | 35 | 2023 |
| Malignant phenotypes in metastatic melanoma are governed by SR-BI and its association with glycosylation and STAT5 activation K Kinslechner, D Schörghofer, B Schütz, M Vallianou, B Wingelhofer, ... Molecular Cancer Research 16 (1), 135-146, 2018 | 33 | 2018 |
| The JAK2/STAT5 signaling pathway as a potential therapeutic target in canine mastocytoma A Keller, B Wingelhofer, B Peter, K Bauer, D Berger, S Gamperl, ... Veterinary and comparative oncology 16 (1), 55-68, 2018 | 28 | 2018 |
| STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway J Pencik, C Philippe, M Schlederer, E Atas, M Pecoraro, ... Molecular Cancer 22 (1), 133, 2023 | 22 | 2023 |
| Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells B Peter, S Bibi, G Eisenwort, B Wingelhofer, D Berger, G Stefanzl, K Blatt, ... Leukemia 32 (4), 1016-1022, 2018 | 22 | 2018 |
| Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas A Orlova, B Wingelhofer, HA Neubauer, B Maurer, A Berger-Becvar, ... Expert opinion on therapeutic targets 22 (1), 45-57, 2018 | 22 | 2018 |
| Emerging epigenetic therapeutic targets in acute myeloid leukemia B Wingelhofer, TCP Somervaille Frontiers in Oncology 9, 850, 2019 | 20 | 2019 |
| STAT5 is Expressed in CD34+/CD38− Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms E Hadzijusufovic, A Keller, D Berger, G Greiner, B Wingelhofer, ... Cancers 12 (4), 1021, 2020 | 16 | 2020 |
| Preloading with L-BPA, L-tyrosine and L-DOPA enhances the uptake of [18F] FBPA in human and mouse tumour cell lines B Wingelhofer, K Kreis, S Mairinger, V Muchitsch, J Stanek, T Wanek, ... Applied Radiation and Isotopes 118, 67-72, 2016 | 16 | 2016 |
| HMG20B stabilizes association of LSD1 with GFI1 on chromatin to confer transcription repression and leukemia cell differentiation block A Maiques-Diaz, L Nicosia, NJ Basma, I Romero-Camarero, F Camera, ... Oncogene 41 (44), 4841-4854, 2022 | 6 | 2022 |
| Therapeutic targeting of EP300/CBP by bromodomain inhibition in acute myeloid leukemia L Nicosia, GJ Spencer, N Brooks, F Amaral, N Basma, J Chadwick, ... Blood 140 (Supplement 1), 8774-8775, 2022 | 4 | 2022 |
| Higher MDMX expression was associated with hypomethylating agent resistance and inferior survival in MDS patients, inferring it a potential therapeutic target YH Wang, CC Lin, K Gurashi, B Wingelhofer, FMR Amaral, CY Yao, ... Leukemia 37 (12), 2507-2511, 2023 | 1 | 2023 |
